Mechanism
JAK1/JAK3 (predominant; also JAK2 at higher concentration)
Assets acting on this target.
- Class
- Small molecule, JAK inhibitor (tofacitinib/tasocitinib, CP-690,550) — this ledger row is a tablet-formulation arm label from a tofacitinib bioavailability study, not a distinct molecule
- Pathway
- JAK-STAT signaling
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.